0.405
3.74%
0.0146
China Sxt Pharmaceuticals Inc (SXTC) Stock Split History
China Sxt Pharmaceuticals Inc has split its stock 3 times since its initial public offering (IPO). The first stock split occurred on February 22, 2021 with the ratio of 1-for-4, meaning that for 4 shares of SXTC owned pre-split, shareholders then owned 1 share. 2 more splits have been implemented since then. The most recent stock split took place on October 05, 2023 on a 1-for-25 basis.
These splits have increased SXTC stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on China Sxt Pharmaceuticals Inc's total market capitalization.
For more detailed information of China Sxt Pharmaceuticals Inc's stock splits, view the table below:
These splits have increased SXTC stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on China Sxt Pharmaceuticals Inc's total market capitalization.
For more detailed information of China Sxt Pharmaceuticals Inc's stock splits, view the table below:
SXTC stock split list
Date | Split Ratio |
---|---|
2023-10-05 | 1 - for - 25 |
2022-05-19 | 1 - for - 20 |
2021-02-22 | 1 - for - 4 |
Will China Sxt Pharmaceuticals Inc Stock Split in 2024?
The answer will depend on the decisions of the company's managers and market volatility. China Sxt Pharmaceuticals Inc has not made an official announcement regarding whether it will enact a stock split or reverse stock split, but it has a history of doing so when SXTC stock prices become too high or too low for retail investors. Therefore, the ultimate decisions will certainly be made by China Sxt Pharmaceuticals Inc's board of directors. Typically, no action is taken until its price per share reaches a specific threshold.
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):